Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.46 |
| ▸ | F10 | P00742 | 3/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.46 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2521152 | 0.87 | LTA4H (0.58) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL8941507 | 0.86 | MEN1 (0.50) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL22061575 | 0.85 | F2 (0.41) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL21330612 | 0.82 | MEN1 (0.51) | HTT | |
| SCHEMBL21330640 | 0.82 | MEN1 (0.48) | ALDH1A1HTTLTA4HMAP4K4NPC1 | |
| SCHEMBL693523 | 0.82 | F2 (0.39) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL21330654 | 0.82 | MAP4K4 (0.55) | F2F10ALDH1A1MAP4K4 | |
| SCHEMBL21330627 | 0.82 | MEN1 (0.52) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL11684536 | 0.82 | MEN1 (0.47) | F2F10PRSS1PRSS2PRSS3 | |
| SCHEMBL4317656 | 0.81 | F2 (0.53) | F2F10PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3543239-B1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | HANGZHOU HEALZEN THERAPEUTICS CO LTD (CN) | 2024-11-13 | — | — | EP | disclosed |
| US-11739090-B2 | Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors | JUMBO DRUG BANK CO., LTD. (CN) | 2023-08-29 | — | — | US | disclosed |
| CN-110483521-B | Reversible covalent Bruton's tyrosine kinase inhibitor, pharmaceutical composition and application thereof | 杭州和正医药有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-10711006-B2 | Selective Bruton's tyrosine kinase inhibitor and use thereof | HANGZHOU HERTZ PHARMACEUTICAL CO., LTD. (CN) | 2020-07-14 | — | — | US | disclosed |
| EP-3543239-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | Hangzhou Hertz Pharmaceutical Co., Ltd. (CN) | 2019-09-25 | — | — | EP | disclosed |
| US-20190276461-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | Hangzhou Healzen Therapeutics Co., Ltd. (CN) | 2019-09-12 | — | — | US | disclosed |
| WO-2018090792-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | 杭州和正医药有限公司 | 2018-05-24 | — | — | WO | disclosed |
| US-5480568-A | FOR LUBRICATING METAL CONTAINING SURFACES | THE DOW CHEMICAL COMPANY (US) | 1996-01-02 | — | — | US | disclosed |
| EP-0630370-A1 | FUNGICIDAL OXAZOLIDINONES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1994-12-28 | — | — | EP | disclosed |
| WO-1993018016-A1 | FUNGICIDAL OXAZOLIDINONES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276461-A1 | SELECTIVE BRUTON'S TYROSINE KINASE INHIBITOR AND USE THEREOF | BTK, BMX, KCNK10 | F2 3757/4885F10 1109/4885PRSS1 3438/4885 |
| US-10711006-B2 | Selective Bruton's tyrosine kinase inhibitor and use thereof | BTK, SYK, LYN | F2 783/4885F10 551/4885PRSS1 3363/4885 |
| US-11739090-B2 | Substituted pyrazlo[3,4-c]pyridines as selective BTK kinase inhibitors | BTK, SYK, LCK | F2 3743/4885F10 2862/4885PRSS1 1419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.